FTC press release: “The Commission has approved publication of a Federal Register Notice regarding the agency’s planned study of authorized generic pharmaceuticals, which was first announced last year. As detailed in the Notice…the Commission proposes to undertake a study to examine both the likely short-term competitive effects of authorized generic drug entry and, to the extent possible, its likely long-term impact on competition by generic drug manufacturers. In its Notice, the Commission responds to public comments regarding its original proposal and describes how it has tailored its information requests to the needs of the planned study. Pursuant to requirements of the Paperwork Reduction Act, the FTC is providing a second opportunity for public comment while requesting that the Office of Management and Budget grant clearance for the proposed information requests. Comments are due to the Commission on or before June 4, 2007.
Commission Consideration of Conducting A Study To Analyze the Use and Likely Short- and Long-Run Competitive Effects of Authorized Generic Drugs in the Prescription Drug Marketplace: Request for Public Comments On Proposed Information Requests to Firms in the Prescription Drug Industry.